Loading organizations...
§ Private Profile · Boston, MA, USA
Biotechnology company developing therapies for autoimmune diseases.
Syntimmune has raised $68.0M across 3 funding rounds.
Syntimmune has raised $68.0M in total across 3 funding rounds.
Syntimmune has raised $68.0M in total across 3 funding rounds.
Syntimmune's investors include Sam Hall, Apple Tree Partners, Baxalta Ventures, Partners Innovation Fund, David de Graaf.
Syntimmune has raised $68.0M across 3 funding rounds. Most recently, it raised $50.0M Series B in June 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 21, 2017 | $50M Series B | SAM Hall | — | Announced |
| Nov 17, 2016 | $8M Series A Plus | — | Apple Tree Partners, Baxalta Ventures, Partners Innovation Fund | Announced |
| Mar 22, 2016 | $10M Series A Plus | David DE Graaf, Baxalta Ventures | Partners Innovation Fund | Announced |